Abstract:Background Lp(a) (lipoprotein[a]) plays an important role in predicting cardiovascular events in patients with coronary artery disease through its proatherogenic and prothrombotic effects. We hypothesized that prolonged dual antiplatelet therapy (DAPT) might be beneficial for patients undergoing percutaneous coronary intervention who had elevated Lp(a) levels. This study aimed to evaluate the effect of Lp(a) on the efficacy and safety of prolonged DAPT versus shortened DAPT in stable patients with coronary artery disease who were treated with a drug‐eluting stent. Methods and Results We selected 3201 stable patients with CAD from the prospective Fuwai Percutaneous Coronary Intervention Registry, of which 2124 patients had Lp(a) ≤30 mg/dL, and 1077 patients had Lp(a) >30 mg/dL. Patients were divided into 4 groups according to Lp(a) levels and the duration of DAPT therapy (≤1 year versus >1 year). The primary end point was major adverse cardiovascular and cerebrovascular event, defined as a composite of all‐cause death, myocardial infarction, or stroke. The median follow‐up time was 2.5 years. Among patients with elevated Lp(a) levels, DAPT >1 year presented lower risk of major adverse cardiovascular and cerebrovascular event and definite/probable stent thrombosis compared with DAPT ≤1 year. In contrast, in patients with normal Lp(a) levels, the risks of major adverse cardiovascular and cerebrovascular event and definite/probable stent thrombosis were not significantly different between the DAPT >1 year and DAPT ≤1 year groups. Prolonged DAPT had 2.4‐times higher risk of clinically relevant bleeding than shortened DAPT in patients with normal Lp(a) levels, although without statistical difference. Conclusions In stable patients with coronary artery disease, who underwent percutaneous coronary intervention with a drug‐eluting stent, prolonged DAPT was associated with reduced risk of cardiovascular events among those with elevated Lp(a) levels, whereas it did not show statistically significant evidence of benefit for reducing ischemic events and tended to increase clinically relevant bleeding among those with normal Lp(a) levels.

Effect of Devated Plasma Lipoprotein (a) on Restenosis after Stent Implantation

To Explore the Relationship between Clinical Serum Markers and Intracoronary in-stent Restenosis

Association Between Plasma Lysophosphatidic Acid and Coronary Stenosis with Coronary Heart Disease

Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement.

Correlation between lipoprotein(a) and recurrent ischemic events post-cerebral vascular stent implantation

Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement

Lipoprotein (a) is Related to In-Stent Neoatherosclerosis Incidence Rate and Plaque Vulnerability: Optical Coherence Tomography Study

[Association between plasma adiponectin level and in-stent restenosis after coronary stenting]

Association Between Plasma Pregnancy-Associated Plasma Protein a and Restenosis after Percutaneous Coronary Angioplasty.

Analysis of risk factors of restenosis after coronary stenting

Predictive value of lectin-like ox-LDL receptor-1 level to restenosis after intracoronary stent implantation

Relationship between pregnancy-associated plasma protein A level and restenosis after elective coronary stenting

EFFECT OF AGGRESSIVE LIPID-LOWERING ON RESTENOSIS IN PATIENTS WITH SUCCESSFUL CORONARY STENT IMPLANTATION

Correlation of Lipoprotein (a) with Clinical Stability and Severity of Coronary Artery Lesions in Patients with Coronary Artery Disease

Correlation Between Plasma Level of Lipoprotein(a) and Severity of Coronary Artery Lesion

How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention?

Relationship Between Plasma Level of IL-18,ox-LDL and the Development of Emergency Percutaneous Coronary Intervention

The predictive value of plasma PAPP-α in development of restenosis after coronary stent implantation.

Predictive Value of Clinical Influence on Angiographic In-Stent Restenosis after Coronary Stent Placement

Association between Lipoprotein (A) and In-Hospital Outcomes in Patients with Acute ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

The relationship between serum LP-PLA_2 and the severity of coronary artery stenosis